Document Detail


Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans.
MedLine Citation:
PMID:  18249200     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Glyceroneogenesis, that is, formation of triglyceride-glycerol from pyruvate, is a critical component of triglyceride fatty acid cycling in vivo. The quantitative contribution of glyceroneogenesis to triglyceride-glycerol and its hormonal regulation have not been examined in humans. We have quantified the contribution of pyruvate to very low-density lipoprotein (VLDL) triglycerides in subjects with type 2 diabetes mellitus using the deuterium labeling of body water technique. Subjects with type 2 diabetes mellitus were studied before and after a 6-month behavioral intervention therapy, during fasting and during a hyperinsulinemic normoglycemic clamp. Response to glucagon infusion was examined in 5 healthy subjects after an overnight fast. Glyceroneogenesis contributed approximately 54% to VLDL triglyceride-glycerol in type 2 diabetes mellitus as compared with approximately 12% contribution of plasma glucose. There was no effect of insulin plus glucose during hyperinsulinemic clamp on glyceroneogenesis even after clinical interventions, when insulin sensitivity had improved. In healthy subjects, the contribution of triosephosphates to plasma VLDL triglycerides was approximately 45%. Glyceroneogenesis, in contrast to glycolysis, is the predominant source of triglyceride-glycerol carbon for VLDL triglycerides in subjects with type 2 diabetes mellitus. The contribution of glyceroneogenesis to triglyceride-glycerol is not affected by short (4 hours) infusion of insulin in type 2 diabetes mellitus.
Authors:
Satish C Kalhan; Elisabetta Bugianesi; Arthur J McCullough; Richard W Hanson; David E Kelley
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  57     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-02-05     Completed Date:  2008-03-11     Revised Date:  2014-09-14    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  305-12     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Diabetes Mellitus, Type 2 / metabolism*
Fatty Acids, Nonesterified / metabolism
Female
Gluconeogenesis / physiology
Glucose / diagnostic use
Glucose Clamp Technique
Glycerol / blood,  metabolism*
Humans
Hypoglycemic Agents / diagnostic use
Insulin / diagnostic use
Lipoproteins, VLDL / blood
Liver / metabolism*
Male
Middle Aged
Pyruvic Acid / metabolism
Triglycerides / biosynthesis*,  blood
Grant Support
ID/Acronym/Agency:
M01 RR000080/RR/NCRR NIH HHS; M01 RR000080-350836/RR/NCRR NIH HHS; M01 RR000080-350872/RR/NCRR NIH HHS; P01 HD011089/HD/NICHD NIH HHS; P01 HD011089-25/HD/NICHD NIH HHS; P01 HD11089/HD/NICHD NIH HHS; P30 DK046204/DK/NIDDK NIH HHS; P30 DK046204-14/DK/NIDDK NIH HHS; P50 HD011089/HD/NICHD NIH HHS; P50 HD011089-209002/HD/NICHD NIH HHS; R01 DK058620/DK/NIDDK NIH HHS; R01 DK058620-03/DK/NIDDK NIH HHS; R01 DK058620-04/DK/NIDDK NIH HHS; R01 DK58620/DK/NIDDK NIH HHS; R01 HD042154/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Fatty Acids, Nonesterified; 0/Hypoglycemic Agents; 0/Insulin; 0/Lipoproteins, VLDL; 0/Triglycerides; 8558G7RUTR/Pyruvic Acid; IY9XDZ35W2/Glucose; PDC6A3C0OX/Glycerol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unearthing the roots of the terpenome.
Next Document:  Diet-induced thermogenesis and substrate oxidation are not different between lean and obese women af...